TB Research

Introducing RpsA Point Mutation Δ438A or D123A into the Chromosome of <i>M. tuberculosis</i> Confirms its Role in Causing Resistance to Pyrazinamide

Wanliang Shi, Peng Cui, Hongxia Niu, Shuo Zhang, Tone Tønjum, Bingdong Zhu, Ying Zhang

bioRxiv (Cold Spring Harbor Laboratory) · 2019-01

Abstract

ABSTRACT Pyrazinamide (PZA) is a unique frontiline drug for shortening tuberculosis treatment, but its mechanisms of action are elusive. We previously identified RpsA as a target of PZA and found an alanine deletion at position 438 (Δ438A) in RpsA associated with PZA resistance, but its role in PZA resistance is controversial. Here, we introduced RpsA mutation Δ438A or D123A into M. tuberculosis chromosome and demonstrated that the introduced RspA mutations are indeed responsible for PZA resistance.

MeSH terms

  • Pyrazinamide
  • Mutation
  • Point mutation
  • Genetics
  • Tuberculosis
  • Mycobacterium tuberculosis
  • Biology